95 related articles for article (PubMed ID: 18418213)
41. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
Zhang QC; Jiang SJ; Zhang S; Ma XB
Asian Pac J Cancer Prev; 2012; 13(7):3471-6. PubMed ID: 22994780
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
[TBL] [Abstract][Full Text] [Related]
43. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.
Yoo GH; Piechocki MP; Oliver J; Lonardo F; Zumstein L; Lin HS; Kim H; Shibuya TY; Shehadeh N; Ensley JF
Laryngoscope; 2004 Nov; 114(11):1871-9. PubMed ID: 15510008
[TBL] [Abstract][Full Text] [Related]
44. The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics.
Wietrzyk J; Milczarek M; Kutner A
Oncol Res; 2007; 16(11):517-25. PubMed ID: 18306931
[TBL] [Abstract][Full Text] [Related]
45. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
[TBL] [Abstract][Full Text] [Related]
46. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
Amin AR; Khuri FR; Chen ZG; Shin DM
Cancer Prev Res (Phila); 2009 Jun; 2(6):538-45. PubMed ID: 19470788
[TBL] [Abstract][Full Text] [Related]
47. Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro.
Erjala K; Zhang N; Sundvall M; Kulmala J; Elenius K; Grénman R
Radiother Oncol; 2007 Oct; 85(1):138-45. PubMed ID: 17923163
[TBL] [Abstract][Full Text] [Related]
48. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer.
Ahsan A; Hiniker SM; Ramanand SG; Nyati S; Hegde A; Helman A; Menawat R; Bhojani MS; Lawrence TS; Nyati MK
Cancer Res; 2010 Apr; 70(7):2862-9. PubMed ID: 20215522
[TBL] [Abstract][Full Text] [Related]
49. Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells.
Landriscina M; Maddalena F; Fabiano A; Piscazzi A; La Macchia O; Cignarelli M
Anticancer Res; 2010 Feb; 30(2):473-80. PubMed ID: 20332457
[TBL] [Abstract][Full Text] [Related]
50. Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.
Klass CM; Choe MS; Hurwitz SJ; Tighiouart M; Zhang X; Chen ZG; Shin DM
Head Neck; 2009 Oct; 31(10):1263-73. PubMed ID: 19399750
[TBL] [Abstract][Full Text] [Related]
51. Cytotoxicity induced by docetaxel in human oral squamous cell carcinoma cell lines.
Iida S; Shimada J; Sakagami H
In Vivo; 2013; 27(3):321-32. PubMed ID: 23606687
[TBL] [Abstract][Full Text] [Related]
52. Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation.
Hambek M; Werner C; Baghi M; Gstöttner W; Knecht R
Eur J Cancer; 2007 Jul; 43(10):1502-7. PubMed ID: 17524637
[TBL] [Abstract][Full Text] [Related]
53. Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells.
Miyanaga S; Ninomiya I; Tsukada T; Okamoto K; Harada S; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Nakamura K; Oyama K; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
Int J Oncol; 2016 Feb; 48(2):517-24. PubMed ID: 26676807
[TBL] [Abstract][Full Text] [Related]
54. Effects of D-allose in combination with docetaxel in human head and neck cancer cells.
Indo K; Hoshikawa H; Kamitori K; Yamaguchi F; Mori T; Tokuda M; Mori N
Int J Oncol; 2014 Nov; 45(5):2044-50. PubMed ID: 25109398
[TBL] [Abstract][Full Text] [Related]
55. Increasing the therapeutic efficacy of docetaxel for cutaneous squamous cell carcinoma through the combined inhibition of phosphatidylinositol 3-kinase/AKT signalling and autophagy.
Wright TJ; McKee C; Birch-Machin MA; Ellis R; Armstrong JL; Lovat PE
Clin Exp Dermatol; 2013 Jun; 38(4):421-3. PubMed ID: 23530461
[TBL] [Abstract][Full Text] [Related]
56. Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in non-small-cell lung cancer.
Kocdor H; Ates H; Aydin S; Cehreli R; Soyarat F; Kemanli P; Harmanci D; Cengiz H; Kocdor MA
Drug Des Devel Ther; 2015; 9():3899-909. PubMed ID: 26251569
[TBL] [Abstract][Full Text] [Related]
57. Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent.
Bijnsdorp IV; Kruyt FA; Gokoel S; Fukushima M; Peters GJ
Cancer Sci; 2008 Nov; 99(11):2302-8. PubMed ID: 18957056
[TBL] [Abstract][Full Text] [Related]
58. Pre-radiation enhances the cytotoxicity of docetaxel in head and neck squamous cell carcinoma cells.
Furuse S; Adachi M; Ijichi K; Ohta S; Torigoe S; Nakazawa M; Miura S; Mitsudo K; Tohnai I
Oncol Rep; 2010 May; 23(5):1339-43. PubMed ID: 20372849
[TBL] [Abstract][Full Text] [Related]
59. [Effect of rapamycin combined with cisplatin on head and neck squamous cancer cells regulated by CCL19].
Liu FY; Zhao ZJ; Li P; Ding X; Sun CF
Zhonghua Kou Qiang Yi Xue Za Zhi; 2011 Apr; 46(4):197-200. PubMed ID: 21612705
[TBL] [Abstract][Full Text] [Related]
60. Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines.
Zou Z; Xie L; Wei J; Yu L; Qian X; Chen J; Wang T; Liu B
BMC Complement Altern Med; 2012 Apr; 12():58. PubMed ID: 22546220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
